Advertisement

Pharmaceutisch Weekblad

, Volume 5, Issue 4, pp 177–181 | Cite as

3,4-Disubstituted phenyliminoimidazolidines as potential prodrugs of the purported dopamine agonist 3,4-dihydroxyphenylimino-2-imidazolidine (DPI)

  • H. A. Houwing
  • J. C. van Oene
  • A. S. Horn
Original Articles

Abstract

Aseries of ether derivatives of the purported dopamine agonist 3,4-dihydroxyphenylimino-2-imidazolidine (Dpi) has been prepared as potential prodrugs of the parent compound due to its relatively poor penetration into the brain. Their effects on both dopamine and noradrenaline utilization in the rat brain have been investigated using the tyrosine hydroxylase inhibitor α-methyl-p-tyrosine. Apart from the parent compound,Dpi, the diphenylmethane ether analogue showed some dopaminergic activity.

Keywords

Public Health Ether Internal Medicine Dopamine Tyrosine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baldessarini, R.J., J.L. Neumeyer, A. Campbell, G. Sperk, V. Ram, G.W. Arana andN.S. Kula (1982)Eur. J. Pharmacol. 77; 87–88.CrossRefPubMedGoogle Scholar
  2. Balsiger, R.W., R.W. Fischer, R. Hirt andE. Giovanni (1953)Helv. Chim. Acta 36, 708–712.CrossRefGoogle Scholar
  3. British Patent 806.060, seeChem. Abs. (1959)53, 18059i.Google Scholar
  4. Cardwell, D., and R.Robinson (1915)J. Chem. Soc., 255–259.Google Scholar
  5. Cools, A.R., andJ. van Rossum (1980)Life Sciences 27, 1237–1253.CrossRefPubMedGoogle Scholar
  6. Horn, A.S., C.J. Grol, D. Dijkstra andA.H. Mulder (1978)J. Med. Chem. 21, 825–828.CrossRefPubMedGoogle Scholar
  7. Horn, A.S., D. Dijkstra, M.G.P. Feenstra, C.J. Grol, H. Rollema andB.H.C. Westerink (1980)Eur. J. Med. Chem. 15, 387–392.Google Scholar
  8. Horn, A.S., D. Dijkstra, T.B.A. Mulder, H. Rollema andB.H.H. Westerink (1981)Eur. J. Med. Chem. 16, 469–472.Google Scholar
  9. Horn, A.S., H. Griever-Kazemier andD. Dijkstra (1982a)J. Med. Chem. 25, 993–996.CrossRefPubMedGoogle Scholar
  10. Horn, A.S., J.B. de Vries, D. Dijkstra andA.H. Mulder (1982b)Eur. J. Pharmacol. 83, 35–45.CrossRefPubMedGoogle Scholar
  11. McOmie, J.F.W. (1973) In:Protective Groups in Organic Chemistry. Plenum Press, London, 157–159.Google Scholar
  12. Miller, R.J., andL.L. Iversen (1974)Naunyn-Schmiedeberg's Arch. Pharmacol. 282, 213–217.CrossRefGoogle Scholar
  13. Oene, J.C. van, H.A. Houwing andA.S. Horn (1982a)Eur. J. Pharmacol. 81, 75–87;Ibidem (1982b).85, 69–77.CrossRefPubMedGoogle Scholar
  14. Ruffalo, R.R., E.L. Yaden, J.E. Waddell andR.D. Dillard (1980)J. Pharmacol. Exp. Ther. 214, 535–540.PubMedGoogle Scholar
  15. Sinkula, A.A. (1975) In: Annual Reports in Medicinal Chemistry, vol. 10. Academic Press, New York, 306–316.Google Scholar
  16. Sloof, G. (1935)Rec. Trav. Chim. (Pays-Bas) 54, 995–1010.Google Scholar
  17. Westerink, B.H.C., andJ. Korf (1977)J. Neurochem. 29, 697–706.PubMedGoogle Scholar
  18. Westerink, B.H.C., andT.B.A. Mulder (1981)J. Neurochem. 36, 1449–1462.PubMedGoogle Scholar
  19. Westerink, B.H.C., D. Dijkstra, M.G.P. Feenstra, G.J. Grol, A.S. Horn, H. Rollema andE. Wirix (1980)Eur. J. Pharmacol. 61, 7–15.CrossRefPubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1983

Authors and Affiliations

  • H. A. Houwing
    • 1
  • J. C. van Oene
    • 1
  • A. S. Horn
    • 1
  1. 1.Department of PharmacyUniversity of GroningenAW GroningenThe Netherlands

Personalised recommendations